butyl propanediamide | 22085-89-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: butyl propanediamide
• 英文别名: n-Butylmalonamide；butyl-malonic acid diamide；Butyl-malonsaeure-diamid；Butylmalonsaeurediamid；2-Butylpropanediamide
• CAS: 22085-89-8
• 化学式: C₇H₁₄N₂O₂
• mdl: MFCD01222705
• 分子量: 158.2
• InChiKey: MLAVHSJBXHTLES-UHFFFAOYSA-N

物化性质

• 熔点：
  198 °C
• 沸点：
  389.3±25.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  butyl propanediamide 在 phosphorus pentoxide 作用下， 以78.7%的产率得到2-丁基丙二腈
  参考文献：
  名称：

  Synthesis and mutagenic activity of alkyl derivatives of 2-amino-9H-pyrido(2,3-b)indole.

  摘要：

  从大豆球蛋白的热解产物中分离出了两种致突变化合物：2-氨基-3-甲基-9H-吡啶[2, 3-b]吲哚（MeAC）和2-氨基-3-乙基-9H-吡啶[2, 3-b]吲哚（EtAC）。这两种化合物以及其他3-取代衍生物是通过2-氨基吲哚与烯胺腈的缩合反应合成的，并测试了它们的致突变活性。与氨基相邻的C-3位的烷基团体积与致突变性强度相关。2-氨基-3-丁基-9H-吡啶[2, 3-b]吲哚及其体积更大的烷基衍生物没有致突变性。

  DOI：

  10.1271/bbb1961.45.2031
• 作为产物：
  描述：

  丙二酰胺 在 氨 、 potassium amide 作用下， 生成 butyl propanediamide
  参考文献：
  名称：

  Shimo; Asami, 1957, vol. 9, p. 319,325

  摘要：

  DOI：

文献信息

• [EN] ARYL DICARBOXAMIDES<br/>[FR] ARYL-DICARBOXAMIDES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2005011685A1

  公开（公告）日：2005-02-10

  The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycernia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an airninocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R1 and R2 are independently from each other is selected from the group consisting of hydrogen or C1-C6-alkyl; R4 and R5 are each independently from each other selected from the group consisting of H, hydroxy, C1-C6 alkyl, carboxy, C1-C6 alkoxy, C1-C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

  本发明涉及式(I)的芳基二羧酰胺及其用于治疗和/或预防肥胖和/或由胰岛素抵抗或高血糖介导的代谢紊乱的使用，包括I型和/或II型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合征(PCOS)。特别是，本发明涉及使用式(I)的芳基二羧酰胺调节，尤其是抑制PTPs的活性。A是氨基甲酰基团；Cy是芳基、杂芳基、芳基-杂芳基、杂芳基-芳基、芳基-芳基、环烷基或杂环组；n为0或1；R1和R2独立地选自由氢或C1-C6-烷基组成的组；R4和R5各自独立地选自由H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基组成的组，或者R4和R5可以形成一个不饱和或饱和的杂环，其中至少R4或R5不是氢或C1-C6烷基。
• Synthesis and mutagenic activity of alkyl derivatives of 2-amino-9H-pyrido(2,3-b)indole.
  作者：Takashi MATSUMOTO、Daisuke YOSHIDA、Hideo TOMITA

  DOI：10.1271/bbb1961.45.2031

  日期：——

  Two mutagenic compounds were isolated from the pyrolysate of soybean globulin: 2-amino-3-methyl-9H-pyrido[2, 3-b]indole (MeAC) and 2-amino-3-ethyl-9H-pyrido[2, 3-b]indole (EtAC). These two and other 3-substituted derivatives were synthesized by the condensation of 2-aminoindole with enaminonitriles, and tested for their mutagenic activity. The bulkiness of the alkyl group at C-3 position adjacent to the amino group was related to the mutagenic strength. 2-Amino-3-butyl-9H-pyrido[2, 3-b]indole and the bulkier alkyl derivatives were not mutagenic.

  从大豆球蛋白的热解产物中分离出了两种致突变化合物：2-氨基-3-甲基-9H-吡啶[2, 3-b]吲哚（MeAC）和2-氨基-3-乙基-9H-吡啶[2, 3-b]吲哚（EtAC）。这两种化合物以及其他3-取代衍生物是通过2-氨基吲哚与烯胺腈的缩合反应合成的，并测试了它们的致突变活性。与氨基相邻的C-3位的烷基团体积与致突变性强度相关。2-氨基-3-丁基-9H-吡啶[2, 3-b]吲哚及其体积更大的烷基衍生物没有致突变性。
• Synthesis of New 5‐Substituted Pyrimidine Acyclonucleosides
  作者：Ahmed F. Khattab

  DOI：10.1080/00397910500498994

  日期：2006.5

  Abstract Acyclonucleosides of pyrimidine were prepared by condensing appropriately silylated 5‐substituted pyrimidines with an acyclic side chain in the form of an acetylated haloalkoxyalcohol and subsequent removal of the protecting acetyl group in base. Also, acyclonucleosides with a 1‐ethoxymethyl side chain have been investigated. The activity against hepatitis B virus (HBV) has been tested.

  摘要 嘧啶的无环核苷是通过将适当的甲硅烷基化的 5-取代嘧啶与乙酰化卤代烷氧基醇形式的无环侧链缩合，然后去除碱中的保护乙酰基来制备的。此外，还研究了具有 1-乙氧基甲基侧链的无环核苷。已经测试了抗乙型肝炎病毒 (HBV) 的活性。
• Hypercoiling polymers and their use in cellular delivery
  申请人：Slater K.H. Nigel

  公开号：US20060172418A1

  公开（公告）日：2006-08-03

  This invention pertains to certain hypercoiling polymers, and their use for the delivery of a payload into a living cell, e.g., into the nucleus of a living cell, which polymer incorporates, or is otherwise associated with, said payload. The payload may be, for example, a therapeutic payload, such as a drug, etc.; a diagnostic payload, such as a detectable label, such as a fluorophore, etc. In preferred embodiments, the hypercoiling polymers are biocompatible; biodegradable; comprise amide linkages; and/or are pseudo-proteins. The present invention also pertains to certain hypercoiling polymers; certain hypercoiling carrier polymers, which incorporate a payload; and certain hypercoiling carrier polymers, otherwise associated with a payload; which are suitable for use in such methods; and methods of diagnosis, treatment, imaging, etc., using such polymers.

  本发明涉及某些超螺旋聚合物及其用于将有效载荷递送到活细胞中，例如递送到活细胞的细胞核中，该聚合物包含或与所述有效载荷相关联。有效载荷可以是治疗有效载荷，例如药物等；诊断有效载荷，例如可检测的标记，如荧光染料等。在优选实施例中，超螺旋聚合物具有生物相容性；可生物降解；包含酰胺键；和/或是伪蛋白质。本发明还涉及某些超螺旋聚合物；某些携带有效载荷的超螺旋载体聚合物；以及某些与有效载荷相关联的超螺旋载体聚合物；它们适用于这种方法的使用；以及使用这样的聚合物进行诊断、治疗、成像等的方法。
• Aryl dicarboxamides
  申请人：Thomas J. Russel

  公开号：US20060189583A1

  公开（公告）日：2006-08-24

  The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an aminocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R 1 and R 2 are independently from each other is selected from the group consisting of hydrogen or C 1 -C 6 -alkyl; R 4 and R 5 are each independently from each other selected from the group consisting of H, hydroxy, C 1 -C 6 alkyl, carboxy, C 1 -C 6 alkoxy, C 1 -C 3 alkyl carboxy, C 2 -C 3 alkenyl carboxy, C 2 -C 3 alkynyl carboxy, amino or R 4 and R 5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R 4 or R 5 is not a hydrogen or C 1 -C 6 alkyl.

  本发明涉及式（I）的芳基二羧酰胺及其用于治疗和/或预防由胰岛素抵抗或高血糖介导的肥胖症和/或代谢紊乱，包括1型和/或2型糖尿病、不良葡萄糖耐受、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式（I）的芳基二羧酰胺来调节，特别是抑制PTP的活性。其中，A是氨基甲酰基；Cy是芳基、杂环芳基、芳基-杂环芳基、杂环芳基-芳基、芳基-芳基、环烷基或杂环基团；n为0或1；R1和R2各自独立地选择自氢或C1-C6烷基的群；R4和R5各自独立地选择自H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基或R4和R5可以形成不饱和或饱和的杂环环，其中R4或R5中至少有一个不是氢或C1-C6烷基。